Core Viewpoint - Alvotech has filed its Annual Report 2025 with the U.S. Securities and Exchange Commission, highlighting its commitment to transparency and regulatory compliance [1]. Company Overview - Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines globally [2]. - The company aims to be a leader in the biosimilars market by providing high-quality, cost-effective products through a fully integrated approach and extensive in-house capabilities [2]. - Alvotech has five biosimilars approved and marketed in various global markets, including those for Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva® [2]. - The current development pipeline includes nine disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [2]. - Alvotech has established strategic commercial partnerships to enhance its global reach and leverage local expertise across markets such as the United States, Europe, Japan, China, and parts of South America, Africa, and the Middle East [2].

Core Viewpoint - Sandoz has launched Pyzchiva® (ustekinumab) autoinjector in Europe, marking it as the first biosimilar of ustekinumab available in an autoinjector format, aimed at improving patient adherence in managing chronic inflammatory diseases [2][3][5]. Product Launch - Pyzchiva® is approved for treating adults with plaque psoriasis, psoriatic arthritis, Crohn's disease, and pediatric plaque psoriasis for patients aged six years and older weighing over 60 kg [2][5]. - The autoinjector features include comfortable self-administration, accurate automatic dosing, reduced injection pain, compact design, and flexible storage options, which may enhance treatment adherence [2][3][6]. Market Context - Europe has the highest prevalence of psoriasis globally, affecting approximately 6.4 million people, and inflammatory bowel diseases like Crohn's disease affect about 2.5 to 3 million people [3][4]. - Non-adherence to biologic therapies can lead to disease progression, increased flares, and higher healthcare costs due to increased hospitalizations and additional treatments [3][4]. Strategic Importance - Pyzchiva® is a significant value driver in Sandoz's growth strategy, with its launch in 23 European markets, starting with Spain [3][4]. - The company entered a development and commercialization agreement with Samsung Bioepis in September 2023, allowing Sandoz to commercialize Pyzchiva® in multiple regions including Brazil, the US, and the European Economic Area [4][5]. Company Overview - Sandoz is a global leader in generic and biosimilar medicines, with a mission to pioneer access for patients, employing over 20,000 people and providing 900 million patient treatments annually, generating substantial healthcare savings [15].